



(12) Translation of
european patent specification

(11) NO/EP 2576546 B1

NORWAY

(19) NO
(51) Int Cl.
C07D 471/04 (2006.01)
A61K 31/437 (2006.01)
A61K 35/00 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2015.12.07
(80)	Date of The European Patent Office Publication of the Granted Patent	2015.07.22
(86)	European Application Nr.	10784398.9
(86)	European Filing Date	2010.11.22
(87)	The European Application's Publication Date	2013.04.10
(30)	Priority	2010.05.26, US, 787682
(84)	Designated Contracting States:	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
	Designated Extension States:	BA ME
(73)	Proprietor	AbbVie Bahamas Ltd., Sassoon House Shirley Street & Victoria Avenue, New Providence, Nassau, BS-Bahamas
(72)	Inventor	BRUNCKO, Milan, 31231 Prairie Ridge, Green OaksIllinois 60048, US-USA DING, Hong, 9 Mayfair Lane, LincolnshireIllinois 60069, US-USA DOHERTY, George, 1605 Bush Court, LibertyvilleIllinois 60048, US-USA ELMORE, Steven, 2139 Ash Lane, NorthbrookIllinois 60062, US-USA HASVOLD, Lisa, 552 Shakespeare Drive, GrayslakeIllinois 60030, US-USA HEXAMER, Laura, 439 Gatewood Lane, GrayslakeIllinois 60030, US-USA KUNZER, Aaron R., 615 W. Burr Oak Drive, ArlingtonIllinois 60004, US-USA SONG, Xiaohong, 34037 Sulkey Drive, GrayslakeIllinois 60030, US-USA SOUERS, Andrew, J., 901 Hinman, Apt. 3A, EvanstonIllinois 60202, US-USA SULLIVAN, Gerard, 1212 Tulip Tree Court, Lake Villallinois 60046, US-USA TAO, Zhi-Fu, 1532 Vineyard Drive, GurneeIllinois 60031, US-USA WANG, Gary, T., 1904 Darnell Street, LibertyvilleIllinois 60048, US-USA WANG, Le, 338 East Colonial Drive, Vernon HillsIllinois 60061, US-USA WANG, Xilu, 1617 Eric Lane, LibertyvilleIllinois 60048, US-USA WENDT, Michael, 1445 Maidstone Drive, Vernon HillsIllinois 60061, US-USA MANTEI, Robert, 4203 Carolyn Court, FranklinWisconsin 53132, US-USA HANSEN, Todd, M., 191 Seymour Avenue, GrayslakeIllinois 60030, US-USA
(74)	Agent or Attorney	Oslo Patentkontor AS, Postboks 7007 Majorstua , 0306 OSLO, Norge

(54)	Title	APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES
------	-------	---

(56)	References Cited:	WO-A1-2005/049594 WO-A1-2007/002325 WO-A2-2010/065824 WO-A2-2010/138588 RU-C2- 2 387 653
------	----------------------	--

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Forbindelse eller et farmasøytisk akseptabelt salt derav, hvor forbindelsen er valgt fra gruppen bestående av:

5 metyl-trans-4-{[(4-{[4-(4-{[2-(4-klorfenyl)-4,4-dimetylcykloheks-1-en-1-yl]metyl}-piperazin-1-yl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloksy)benzoyl]sulfamoyl}-2-nitrofenyl)amino]metyl}cykloheksankarboksylat;

trans-4-{[(4-{[4-(4-{[2-(4-klorfenyl)-4,4-dimetylcykloheks-1-en-1-yl]metyl}-piperazin-1-yl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloksy)benzoyl]sulfamoyl}-2-nitrofenyl)-amino]metyl}cykloheksankarboksylsyre;

10 N-(4-{[4-(4-{[2-(4-klorfenyl)-4,4-dimetylcykloheks-1-en-1-yl]metyl}piperazin-1-yl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloksy)benzoyl]sulfamoyl}-2-nitrofenyl)-4-cyanopiperidin-1-karboksamid;

15 4-(4-{[2-(4-klorfenyl)-4,4-dimetylcykloheks-1-en-1-yl]metyl}piperazin-1-yl)-N-{[4-({[cis-4-(metoksymetyl)cykloheksyl]metyl}amino)-3-nitrofenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridin-5-yloksy)benzamid;

4-(4-{[2-(4-klorfenyl)-4,4-dimetylcykloheks-1-en-1-yl]metyl}piperazin-1-yl)-N-{[4-({[trans-4-(metoksymetyl)cykloheksyl]metyl}amino)-3-nitrofenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridin-5-yloksy)benzamid;

20 4-(4-{[2-(4-klorfenyl)-4,4-dimetylcykloheks-1-en-1-yl]metyl}piperazin-1-yl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloksy)-N-{[1-(tetrahydro-2H-pyran-4-ylmetyl)-1H-benzotriazol-5-yl]sulfonyl}benzamid;

N-({5-klor-6-[(2-okso-1-oksa-3-azaspiro[4.5]dec-8-yl)metoksy]pyridin-3-yl}-sulfonyl)-4-(4-{[2-(4-klorfenyl)-4,4-dimetylcykloheks-1-en-1-yl]metyl}piperazin-1-yl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloksy)benzamid;

25 N-(4-{[4-(4-{[2-(4-klorfenyl)-4,4-dimetylcykloheks-1-en-1-yl]metyl}piperazin-1-yl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloksy)benzoyl]sulfamoyl}-2-nitrofenyl)-4-metoksy-piperidin-1-karboksamid;

- N-({5-klor-6-[(2-metyl-4,5,6,7-tetrahydro-1,3-benzotiazol-5-yl)metoksy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-klorfenyl)-4,4-dimetylcykloheks-1-en-1-yl]metyl}piperazin-1-yl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloksy)benzamid;
- 5 4-(4-{[2-(4-klorfenyl)-4,4-dimetylcykloheks-1-en-1-yl]metyl}piperazin-1-yl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloksy)-N-{[1-(tetrahydro-2H-pyran-4-ylmetyl)-1H-pyrrolo[2,3-b]pyridin-5-yl}sulfonyl}benzamid;
- 4-(4-{[2-(4-klorfenyl)-4,4-dimetylcykloheks-1-en-1-yl]metyl}piperazin-1-yl)-N-{[3-klor-1-(tetrahydro-2H-pyran-4-ylmetyl)-1H-pyrrolo [2,3-b]pyridin-5-yl}sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridin-5-yloksy)benzamid;
- 10 4-(4-{[2-(4-klorfenyl)-4-(metoksymetyl)-4-metylcykloheks-1-en-1-yl]metyl}-piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmetyl)amino]fenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloksy)benzamid;
- N-[(4-{[4,4-bis(hidroksymetyl)cykloheksyl]metoksy}-3-nitrofenyl)sulfonyl]-4-(4-{[2-(4-klorfenyl)-4,4-dimetylcykloheks-1-en-1-yl]metyl}piperazin-1-yl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloksy)benzamid;
- 15 N-(2-klor-4-{[4-(4-{[2-(4-klorfenyl)-4,4-dimetylcykloheks-1-en-1-yl]metyl}-piperazin-1-yl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloksy)benzoyl]sulfamoyl}fenyl)-4-metoksypiperidin-1-karboksamid;
- N-(2-klor-4-{[4-(4-{[2-(4-klorfenyl)-4,4-dimetylcykloheks-1-en-1-yl]metyl}-piperazin-1-yl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloksy)benzoyl]sulfamoyl}fenyl)-4-
- 20 cyanopiperidin-1-karboksamid;
- N-(2-klor-4-{[4-(4-{[2-(4-klorfenyl)-4,4-dimetylcykloheks-1-en-1-yl]metyl}-piperazin-1-yl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloksy)benzoyl]sulfamoyl}fenyl)-4-hidroksy-4-metyl piperidin-1-karboksamid;
- 25 N-(2-klor-4-{[4-(4-{[2-(4-klorfenyl)-4,4-dimetylcykloheks-1-en-1-yl]metyl}-piperazin-1-yl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloksy)benzoyl]sulfamoyl}fenyl)-4-(metoksymetyl)piperidin-1-karboksamid;

N-[(5-klor-6-{[(5r,8r)-2-okso-1-oksa-3-azaspiro[4.5]dec-8-yl]metoksy}pyridin-3-yl)-sulfonyl]-4-(4-{[2-(4-klorfenyl)-4,4-dimetylcykloheks-1-en-1-yl]metyl}piperazin-1-yl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloksy)benzamid;

5 N-[(5-klor-6-{[(5s,8s)-2-okso-1-oksa-3-azaspiro[4.5]dec-8-yl]metoksy}pyridin-3-yl)-sulfonyl]-4-(4-{[2-(4-klorfenyl)-4,4-dimetylcykloheks-1-en-1-yl]metyl}piperazin-1-yl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloksy)benzamid;

N-(2-klor-4-{[4-(4-{[2-(4-klorfenyl)-4,4-dimetylcykloheks-1-en-1-yl]metyl}-piperazin-1-yl)-2-(1H-pyrrolo [2,3-b]pyridin-5-yloksy)benzoyl]sulfamoyl}fenyl)-4-(morfolin-4-yl)piperidin-1-karboksamid;

10 N-[(5-klor-6-{[trans-4-hidroksy-4-(metoksymetyl)cykloheksyl]metoksy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-klorfenyl)-4,4-dimetylcykloheks-1-en-1-yl]metyl}piperazin-1-yl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloksy)benzamid;

15 N-[(5-klor-6-{[cis-4-hidroksy-4-(hidroksymetyl)cykloheksyl]metoksy}pyridin-3-yl)-sulfonyl]-4-(4-{[2-(4-klorfenyl)-4,4-dimetylcykloheks-1-en-1-yl]metyl}piperazin-1-yl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloksy)benzamid;

N-[(5-klor-6-{[trans-4-hidroksy-4-(hidroksymetyl)cykloheksyl]metoksy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-klorfenyl)-4,4-dimetylcykloheks-1-en-1-yl]metyl}piperazin-1-yl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloksy)benzamid;

20 N-[(5-klor-6-{[4-fluor-1-(oksetan-3-yl)piperidin-4-yl]metoksy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-klorfenyl)-5-metoksy-5-metylcykloheks-1-en-1-yl]metyl}piperazin-1-yl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloksy)benzamid;

4-(4-{[2-(4-klorfenyl)cykloheks-1-en-1-yl]metyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmetyl)amino]fenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloksy)benzamid;

25 4-(4-klorfenyl)-1-metyl-3-[(4-{4-[({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmetyl)-amino]fenyl}sulfonyl]karbamoyl]-3-(1H-pyrrolo[2,3-b]pyridin-5-yloksy)fenyl}-piperazin-1-yl)metyl]cykloheks-3-en-1-karboksylsyre; og

N-[(5-klor-6-{[1-(oksetan-3-yl)piperidin-4-yl]metoksy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-klorfenyl)-4,4-dimetylcykloheks-1-en-1-yl]metyl}piperazin-1-yl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloksy)benzamid.

2. Farmasøytisk sammensetning omfattende en eksipiens og en terapeutisk
5 virksam mengde av en forbindelse eller et farmasøytisk akseptabelt salt ifølge krav 1.

3. Sammensetning for anvendelse i en fremgangsmåte for behandling av
blærekreft, hjernekreft, brystkreft, benmargskreft, livmorhalskreft, kronisk
lymfocytisk leukemi, kolorektal kreft, spiserørskreft, hepatocellulær kreft,
lymfoblastisk leukemi, follikulært lymfom, lymfoid ondartethet av T-celle- eller B-
10 celle-opphav, melanom, myelogen leukemi, myelom, kreft i munnhulen, eggstokkreft,
ikke-småcellet lungekreft, prostatakreft, småcellet lungekreft eller miltkreft i en
pasient, hvilken sammensetning omfatter en terapeutisk virksam mengde av en
forbindelse eller et farmasøytisk akseptabelt salt ifølge krav 1.

4. Sammensetning for anvendelse i en fremgangsmåte for behandling av
15 blærekreft, hjernekreft, brystkreft, benmargskreft, livmorhalskreft, kronisk
lymfocytisk leukemi, kolorektal kreft, spiserørskreft, hepatocellulær kreft,
lymfoblastisk leukemi, follikulært lymfom, lymfoid ondartethet av T-celle- eller B-
celle-opphav, melanom, myelogen leukemi, myelom, kreft i munnhulen,
eggstokkreft, ikke-småcellet lungekreft, prostatakreft, småcellet lungekreft eller
20 miltkreft i en pasient, hvilken sammensetning omfatter en terapeutisk virksam
mengde av en forbindelse eller et farmasøytisk akseptabelt salt ifølge krav 1 og en
terapeutisk virksam mengde av et ytterligere terapeutisk middel eller flere enn ett
ytterligere terapeutisk middel.